TITLE

Rationale and design of the CAPAMIS study: Effectiveness of pneumococcal vaccination against community-acquired pneumonia, acute myocardial infarction and stroke

AUTHOR(S)
Vila-Corcoles, Angel; Hospital-Guardiola, Inmaculada; Ochoa-Gondar, Olga; de Diego, Cinta; Salsench, Elisabet; Raga, Xavier; Fuentes-Bellido, Cruz M.
PUB. DATE
January 2010
SOURCE
BMC Public Health;2010, Vol. 10, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: The 23-valent polysaccharide pneumococcal vaccine (PPV-23) is recommended for elderly and highrisk people, although its effectiveness is controversial. Some studies have reported an increasing risk of acute vascular events among patients with pneumonia, and a recent case-control study has reported a reduction in the risk of myocardial infarction among patients vaccinated with PPV-23. Given that animal experiments have shown that pneumococcal vaccination reduces the extent of atherosclerotic lesions, it has been hypothesized that PPV-23 could protect against acute vascular events by an indirect effect preventing pneumonia or by a direct effect on oxidized low-density lipoproteins. The main objective of this study is to evaluate the clinical effectiveness of PPV-23 in reducing the risk of pneumonia and acute vascular events (related or nonrelated with prior pneumonia) in the general population over 60 years. Methods/Design: Cohort study including 27,000 individuals 60 years or older assigned to nine Primary Care Centers in the region of Tarragona, Spain. According to the reception of PPV-23 before the start of the study, the study population will be divided into vaccinated and nonvaccinated groups, which will be followed during a consecutive 30-month period. Primary Care and Hospitals discharge databases will initially be used to identify study events (community-acquired pneumonia, hospitalisation for acute myocardial infarction and stroke), but all cases will be further validated by checking clinical records. Multivariable Cox regression analyses estimating hazard ratios (adjusted for age, sex and comorbidities) will be used to estimate vaccine effectiveness. Discussion: The results of the study will contribute to clarify the controversial effect of the PPV-23 in preventing community-acquired pneumonia and they will be critical in determining the posible role of pneumococcal vaccination in cardiovascular prevention.
ACCESSION #
48497328

 

Related Articles

  • Pathology: At the heart of the problem. Willyard, Cassandra // Nature;1/31/2013 Supplement, Vol. 493 Issue 7434, pS10 

    The article discusses the molecular pathways underlying the major risk factors of heart disease particularly the connection between high cholesterol and cardiac disease. It notes that a surplus of low-density lipoprotein (LDL) can lodge in artery walls which promotes the formation of plaque and...

  • ApoB: Better predictor of CHD?  // Cortlandt Forum;Feb2006, Vol. 19 Issue 2, p15 

    The article reports that apolipoprotein B (AB) and non-high-density lipoprotein cholesterol are better predictors of coronary heart disease (CHD) than low-density lipoprotein (LDL). In a study comparing 243 men who experienced fatal or nonfatal myocardial infarction with 496 matched controls who...

  • Design of a randomized controlled trial of disclosing genomic risk of coronary heart disease: the Myocardial Infarction Genes (MI-GENES) study. Kullo, Iftikhar J.; Jouni, Hayan; Olson, Janet E.; Montori, Victor M.; Bailey, Kent R. // BMC Medical Genomics;Aug2015, Vol. 8 Issue 1, p1 

    Background: Whether disclosure of a genetic risk score (GRS) for a common disease influences relevant clinical outcomes is unknown. We describe design of the Myocardial Infarction Genes (MI-GENES) Study, a randomized clinical trial to assess whether disclosing a GRS for coronary heart disease...

  • A New Low for Cholesterol. Goodman, Brenda // Arthritis Today;May/Jun2009, Vol. 23 Issue 3, p39 

    The article presents a new study conducted regarding the new low-density lipoprotein (LDL) level of cholesterol for heart attack. The national research based on the 136,000 patients admitted to hospitals shows that a normal LDL cholesterol level can also lead to heart attack. According to...

  • Pneumococcal vaccination and myocardial infarction. Skowronski, Danuta M.; Janjua, Naveed Z.; Hottes, Travis S.; Patrick, David M.; De Serres, Gaston // CMAJ: Canadian Medical Association Journal;2/3/2009, Vol. 180 Issue 3, p319 

    Several letters to the editor are presented in response to the article by François Lamontagne and colleagues on the association between receipt of pneumococcal vaccination and a lower risk of myocardial infarction.

  • High-dose statin lowers MI risk.  // Cortlandt Forum;4/25/2004, Vol. 17 Issue 4, p18 

    Details results of two multicenter trials which show that high doses of Lipitor or atorvastatin lower low density lipoproteins (LDL) levels, halt plaque progression in patients with moderately high cholesterol and reduce heart patients' risk of a myocardial infarction. Comparison of the...

  • Influence of Peripheral Artery Disease and Statin Therapy on Apolipoprotein Profiles. Gardner, Andrew W.; Alaupovic, Petar; Parker, Donald E.; Montgomery, Polly S.; Esponda, Omar L.; Casanegra, Ana I. // International Journal of Vascular Medicine;2013, p1 

    Apolipoprotein B is a stronger predictor of myocardial infarction than LDL cholesterol, and it is inversely related to physical activity and modifiable with exercise training. As such, apolipoprotein measures may be of particular relevance for subjects with PAD and claudication. We compared...

  • Cardiovascular risk factors in BanovićI coal mine miners. Becarevic, Munevera; Burgic, Esad // HealthMed;2012, Vol. 6 Issue 7, p1067 

    Global cardiovascular risk is probability to suffer heart attack or stroke in certain period of life and it depends on risk factors (RF) such as metabolical factors (total cholesterol, HDL cholesterol, glucoses metabolism disturbance), some biological factors (blood pressure) and some life style...

  • A strategy to reduce cardiovascular disease by more than 80%. Wald, N.J.; Law, M.R. // BMJ: British Medical Journal (International Edition);6/28/2003, Vol. 326 Issue 7404, p1419 

    Abstract Objectives: To determine the combination of drugs and vitamins, and their doses, for use in a single daily pill to achieve a large effect in preventing cardiovascular disease with minimal adverse effects. The strategy was to simultaneously reduce four cardiovascular risk factors (low...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics